Why Medicaid cuts could be a ‘crisis’ for people with disabilities
If the new administration slashes federal Medicaid spending, millions of people with disabilities would be cut off from critical health care services.
Related Articles
Where are the personal journals from the early days of HIV?
For years, John Fleischman carried the journal of his late mentor, who died from HIV/AIDS. He finally found the perfect home for it at the…
Where are the personal journals from the early days of HIV?
For years, John Fleischman carried the journal of his late mentor, who died from HIV/AIDS. He finally found the perfect home for it at the…
What does Medicaid look like in a second Trump presidency?
This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.
Using lab-grown human mini-brains, scientists find links between head trauma, herpes, and Alzheimer’s
Research published Tuesday is the first to connect the dots between a common herpes virus, head injury, and Alzheimer’s.
What to know about a controversial new study on fluoride and IQ
Critics of a new study on water fluoridation and IQ are questioning its data and methodology.
FDA’s new guidance on AI in drug development centers the risk introduced by the technology
After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug development.
Using lab-grown human mini-brains, scientists find links between head trauma, herpes, and Alzheimer’s
Research published Tuesday is the first to connect the dots between a common herpes virus, head injury, and Alzheimer’s.
FDA looks to clarify confirmatory trial mandate for accelerated approvals
In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory trials at least be underway at the…
They may be ‘miracle’ drugs, but obesity meds call for a team approach
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single physician to handle.
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs…